NCT07169175 is a Phase 1, PHASE2 clinical trial of SNUG01 in Amyotrophic Lateral Sclerosis (ALS), sponsored by SineuGene Therapeutics Co., Ltd..

Who is sponsoring NCT07169175?

NCT07169175 is sponsored by SineuGene Therapeutics Co., Ltd..

What drugs are being tested in NCT07169175?

Interventions in NCT07169175: SNUG01.

What condition does NCT07169175 study?

NCT07169175 studies Amyotrophic Lateral Sclerosis (ALS).

Is NCT07169175 still recruiting?

NCT07169175 is currently not yet recruiting. Last updated 11 September 2025.

Last reviewed 2025-09-11 · How we verify

NCT07169175

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase Ⅰ/Ⅱa Study of SNUG01 in Adult Subjects With ALS

Not yet recruiting Phase 1, PHASE2 Last updated 11 September 2025

What this trial tests

Phase 1, PHASE2 trial testing SNUG01 in Amyotrophic Lateral Sclerosis (ALS) in 21 participants. Not yet recruiting.

Timeline

1 December 2025

Primary endpoint
30 March 2028

30 September 2028

Quick facts

Lead sponsor	SineuGene Therapeutics Co., Ltd.
Phase	Phase 1, PHASE2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	21
Start date	1 December 2025
Primary completion	30 March 2028
Estimated completion	30 September 2028
Sites	4 locations across China, United States

Drugs / interventions tested

SNUG01 — full drug profile →

Conditions studied

Amyotrophic Lateral Sclerosis (ALS) — all drugs for Amyotrophic Lateral Sclerosis (ALS) →

Sponsor

SineuGene Therapeutics Co., Ltd.

Who can join

Adults 18 to 80, any sex, with Amyotrophic Lateral Sclerosis (ALS). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to evaluate the safety, tolerability and preliminary efficacy of SNUG01 in in adult subjects with Amyotrophic Lateral Sclerosis (ALS).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of SNUG01

Trials testing the same drug.

NCT06645197 — An IIT Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Injection o · EARLY_PHASE1 · not yet recruiting

Other recruiting trials for Amyotrophic Lateral Sclerosis (ALS)

Currently open trials in the same condition.

NCT06608004 — Influence of Olfacto-gustatory Sensoriality on the Nutritional Status of Patients With Amyotrophic Lateral Sclerosis · recruiting
NCT07187388 — Investigating the Impact of Electrical Stimulation on Facial Pain, Jaw Movement and Oral Health in People With Motor Neu · NA · recruiting
NCT07233148 — Healing ALS Registry Observational Study (HAROS) · recruiting
NCT07257302 — Lung Insufflation Capacity Training and Respiratory Function in Amyotrophic Lateral Sclerosis · NA · recruiting
NCT07118319 — The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Am · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07169175 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by SineuGene Therapeutics Co., Ltd.
Last refreshed: 11 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07169175.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing